Urothelial Cancer
J4G-MC-JZVD: FORAGER-2 (JZVD: Ph 3, Randomized Double-blind, Placebo-controlled, Multicenter, Study of LOXO-435(LY3866288)) in combination with Enfortumab Vedotin plus Pembrolizumab in Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 genetic alteration.
- Details
ClinicalTrials.gov ID:
NCT07218380
Diagnosis Type:
NA
USOR Number:
- Address
,
P: